89bio EBITDA per Share
Delisted·Oct 29, 2025
The EBITDA per Share of 89bio (ETNB) as of Aug 16, 2026 is -3.32 USD. In the previous year, EBITDA per Share was -1.87 USD — a change of 77.04% (lower).
Get this data via API
Financial Data API
EBITDA per Share
-3.32USD
YoY
77.04%
Last updated:
EBITDA per Share of 89bio is 2026 -3.32 USD. EBITDA per Share of 89bio was 2025 -1.87 USD. It decreases by 77.04% lower compared to the previous year.
Access this data via the Eulerpool API
89bio Stock analysis
What does 89bio do? 89Bio Inc is an emerging biopharmaceutical company focused on developing drugs to treat metabolic and liver diseases. The company was founded in 2018 and is headquartered in San Francisco, California.
89Bio's business model is based on utilizing innovative science and technology to develop novel and effective therapeutic options for diseases that are currently only limitedly treatable. The company has assembled an interdisciplinary team of scientists, physicians, and entrepreneurs with extensive experience in the pharmaceutical industry.
89Bio has two main divisions: Endocrine and Liver Diseases. In the field of Endocrine Diseases, the company has developed a platform technology based on the binding of human proteins with high affinity and specificity. This technology aims to treat hormone deficiencies in patients with certain endocrine disorders. An example of the application of this technology is 89Bio's leading product, BIO89-100, which is currently in development for the treatment of hypoparathyroidism.
The second division of 89Bio is Liver Diseases. The company has developed a pipeline of drug candidates for liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These diseases are a growing public health concern worldwide as they are associated with obesity, diabetes, and other metabolic disorders. The leading product in this pipeline is BIO89-1000, which aims to improve liver function by activating a specific group of receptors in the body.
In recent years, 89Bio has established strong partnerships with leading companies in the pharmaceutical industry to accelerate its research and development. The company has also received funding from renowned global investors to support its growth and expansion.
Overall, 89Bio Inc has a promising future as it focuses on developing therapeutic options for serious diseases that are currently inadequately treated. The company has a strong foundation in research and technology, as well as the experience of its leadership team and partnerships. With its new and innovative approaches, 89Bio can make a sustainable contribution to improving healthcare and patient well-being. 89bio is one of the most popular companies on Eulerpool.
Frequently Asked Questions about 89bio stock
EBITDA per Share of 89bio is -3.32 USD in 2026.
EBITDA per Share of 89bio changed from -1.87 USD to -3.32 USD, representing a 77.04% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBITDA per Share 89bio since 2006 – with annual values, charts, and detailed analysis.
EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.
Access this data via the Eulerpool API
Income Statement — 89bio
All Key Metrics — 89bio
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth